JP2014510708A - インダゾール誘導体およびピロロピリジン誘導体ならびにその医薬用途 - Google Patents
インダゾール誘導体およびピロロピリジン誘導体ならびにその医薬用途 Download PDFInfo
- Publication number
- JP2014510708A JP2014510708A JP2013547047A JP2013547047A JP2014510708A JP 2014510708 A JP2014510708 A JP 2014510708A JP 2013547047 A JP2013547047 A JP 2013547047A JP 2013547047 A JP2013547047 A JP 2013547047A JP 2014510708 A JP2014510708 A JP 2014510708A
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- methyl
- oxadiazol
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCCC(C)=C(C(C(C)=C)=C(C)C(C)=C(C)*)N(C)C1*[U](*B*)**1 Chemical compound CCCC(C)=C(C(C(C)=C)=C(C)C(C)=C(C)*)N(C)C1*[U](*B*)**1 0.000 description 23
- JEBRCXVVNPFMDQ-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1C(O)=O)CC1OC)=O Chemical compound CC(C)(C)OC(N(CCC1C(O)=O)CC1OC)=O JEBRCXVVNPFMDQ-UHFFFAOYSA-N 0.000 description 1
- GFKJGIZXOHDIEA-UHFFFAOYSA-N CC(C)c(c1ccc2)n[nH]c1c2F Chemical compound CC(C)c(c1ccc2)n[nH]c1c2F GFKJGIZXOHDIEA-UHFFFAOYSA-N 0.000 description 1
- RZZVOSKOKTUJQU-QGOAFFKASA-N CC(C)c(c1ccc2)n[n](/C(/N)=C/N(C(CC3)CCN3C(OC(C)(C)C)=O)N)c1c2F Chemical compound CC(C)c(c1ccc2)n[n](/C(/N)=C/N(C(CC3)CCN3C(OC(C)(C)C)=O)N)c1c2F RZZVOSKOKTUJQU-QGOAFFKASA-N 0.000 description 1
- DWFJEBGSYPLIPK-XNTDXEJSSA-N CC(C)c(c1ccc2)n[n](/C(/N)=C/N(C3CCNCC3)N)c1c2F Chemical compound CC(C)c(c1ccc2)n[n](/C(/N)=C/N(C3CCNCC3)N)c1c2F DWFJEBGSYPLIPK-XNTDXEJSSA-N 0.000 description 1
- RVBGJIWRUYUXGK-UHFFFAOYSA-N CC(C)c(c1cccc(F)c11)n[n]1-c1n[o]c(C(C2)CC2=O)n1 Chemical compound CC(C)c(c1cccc(F)c11)n[n]1-c1n[o]c(C(C2)CC2=O)n1 RVBGJIWRUYUXGK-UHFFFAOYSA-N 0.000 description 1
- QXCVVHYLAPOOFN-UHFFFAOYSA-N CC(C)c(c1cccc(F)c11)n[n]1-c1n[o]c(C2CCCCCCCC2)n1 Chemical compound CC(C)c(c1cccc(F)c11)n[n]1-c1n[o]c(C2CCCCCCCC2)n1 QXCVVHYLAPOOFN-UHFFFAOYSA-N 0.000 description 1
- LDIQOGASSNBOTI-UHFFFAOYSA-N CC(C)c(c1cccc(F)c11)n[n]1-c1n[o]c(C2CCNCC2)n1 Chemical compound CC(C)c(c1cccc(F)c11)n[n]1-c1n[o]c(C2CCNCC2)n1 LDIQOGASSNBOTI-UHFFFAOYSA-N 0.000 description 1
- ZSFAZNJBEGJGAS-UHFFFAOYSA-N CC(C)c(c1ccccc11)n[n]1-c1n[o]c(C2CCN(CCCOC)CC2)n1 Chemical compound CC(C)c(c1ccccc11)n[n]1-c1n[o]c(C2CCN(CCCOC)CC2)n1 ZSFAZNJBEGJGAS-UHFFFAOYSA-N 0.000 description 1
- PRGSQEISVOCNLQ-UHFFFAOYSA-N CC(C)c(c1ccccc11)n[n]1-c1n[o]c(C2CCNCC2)n1 Chemical compound CC(C)c(c1ccccc11)n[n]1-c1n[o]c(C2CCNCC2)n1 PRGSQEISVOCNLQ-UHFFFAOYSA-N 0.000 description 1
- FVNWQISOXYMLPT-UHFFFAOYSA-N CCOC(C(CCN(C1)C(OC(C)(C)C)=O)=C1OC)=O Chemical compound CCOC(C(CCN(C1)C(OC(C)(C)C)=O)=C1OC)=O FVNWQISOXYMLPT-UHFFFAOYSA-N 0.000 description 1
- WCTXJAXKORIYNA-UHFFFAOYSA-N CCOC(C(CCN(C1)C(OC(C)(C)C)=O)C1=O)=O Chemical compound CCOC(C(CCN(C1)C(OC(C)(C)C)=O)C1=O)=O WCTXJAXKORIYNA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013547047A JP2014510708A (ja) | 2011-06-07 | 2012-06-06 | インダゾール誘導体およびピロロピリジン誘導体ならびにその医薬用途 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011127688 | 2011-06-07 | ||
| JP2011127688 | 2011-06-07 | ||
| JP2013547047A JP2014510708A (ja) | 2011-06-07 | 2012-06-06 | インダゾール誘導体およびピロロピリジン誘導体ならびにその医薬用途 |
| PCT/JP2012/065052 WO2012169649A1 (en) | 2011-06-07 | 2012-06-06 | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510708A true JP2014510708A (ja) | 2014-05-01 |
| JP2014510708A5 JP2014510708A5 (https=) | 2014-06-19 |
Family
ID=47296200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547047A Pending JP2014510708A (ja) | 2011-06-07 | 2012-06-06 | インダゾール誘導体およびピロロピリジン誘導体ならびにその医薬用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140057895A1 (https=) |
| EP (1) | EP2718283A4 (https=) |
| JP (1) | JP2014510708A (https=) |
| KR (1) | KR20140041519A (https=) |
| CN (1) | CN103748087A (https=) |
| AU (1) | AU2012267797A1 (https=) |
| BR (1) | BR112013030939A2 (https=) |
| CA (1) | CA2833507A1 (https=) |
| MX (1) | MX2013014427A (https=) |
| RU (1) | RU2013157374A (https=) |
| TW (1) | TW201311674A (https=) |
| WO (1) | WO2012169649A1 (https=) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019533022A (ja) * | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US12180221B2 (en) | 2018-03-23 | 2024-12-31 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US12268687B2 (en) | 2019-11-13 | 2025-04-08 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US12433880B2 (en) | 2017-01-06 | 2025-10-07 | Janssen Pharmaceutica Nv | Methods for the treatment of neurological disorders |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016028016A (ja) * | 2012-12-12 | 2016-02-25 | 大日本住友製薬株式会社 | オキサジアゾール誘導体とその医薬用途 |
| CU24275B1 (es) | 2013-02-22 | 2017-10-05 | Pfizer | Derivados de cicloalquilo pirrolo [2,3-d] pirimidina-4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos |
| EP3180344B1 (en) | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| KR102140508B1 (ko) | 2016-09-28 | 2020-08-03 | 경희대학교 산학협력단 | 헌팅턴병의 예방 또는 치료용 조성물 |
| PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
| US12590083B2 (en) * | 2019-01-25 | 2026-03-31 | University Of Virginia Patent Foundation | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy |
| CA3189027A1 (en) | 2020-07-11 | 2022-01-20 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CN116836157A (zh) * | 2022-03-25 | 2023-10-03 | 星希尔生物科技(上海)有限公司 | 一种噁二唑衍生物及其制备方法和用途 |
| CN115417772B (zh) * | 2022-09-26 | 2024-07-19 | 无锡双启科技有限公司 | 一种3-硝基-4-氟苯甲醚的制备方法 |
| CN115947690B (zh) * | 2022-12-13 | 2025-04-08 | 安徽医科大学 | 一种吲唑分子砌块的制备方法及其在药物合成中的应用 |
| WO2025045837A1 (en) | 2023-08-31 | 2025-03-06 | Syngenta Crop Protection Ag | Pesticidally active indazole compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009543836A (ja) * | 2006-07-14 | 2009-12-10 | グラクソ グループ リミテッド | インドール化合物 |
| WO2012069917A1 (en) * | 2010-11-26 | 2012-05-31 | Lupin Limited | Bicyclic gpr119 modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1291569B1 (it) * | 1997-04-15 | 1999-01-11 | Angelini Ricerche Spa | Indazolammidi come agenti serotoninergici |
| US6069152A (en) * | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| CA2588037A1 (en) * | 2004-12-22 | 2006-06-29 | Theravance, Inc. | Indazole-carboxamide compounds |
| US7906532B2 (en) * | 2005-07-22 | 2011-03-15 | Pfizer Inc. | Indazole derivatives |
| GB0901487D0 (en) * | 2009-01-30 | 2009-03-11 | Movetis N V | Asthma Therapy |
| AP3307A (en) * | 2011-09-19 | 2015-06-30 | Suven Life Sciences Ltd | Heteroaryl compounds as 5-HT4 receptor ligands |
-
2012
- 2012-06-06 KR KR1020137032070A patent/KR20140041519A/ko not_active Withdrawn
- 2012-06-06 JP JP2013547047A patent/JP2014510708A/ja active Pending
- 2012-06-06 RU RU2013157374/04A patent/RU2013157374A/ru not_active Application Discontinuation
- 2012-06-06 CA CA2833507A patent/CA2833507A1/en not_active Abandoned
- 2012-06-06 US US14/005,659 patent/US20140057895A1/en not_active Abandoned
- 2012-06-06 EP EP12796621.6A patent/EP2718283A4/en not_active Withdrawn
- 2012-06-06 WO PCT/JP2012/065052 patent/WO2012169649A1/en not_active Ceased
- 2012-06-06 CN CN201280025823.9A patent/CN103748087A/zh active Pending
- 2012-06-06 MX MX2013014427A patent/MX2013014427A/es unknown
- 2012-06-06 AU AU2012267797A patent/AU2012267797A1/en not_active Abandoned
- 2012-06-06 BR BR112013030939A patent/BR112013030939A2/pt not_active IP Right Cessation
- 2012-06-07 TW TW101120435A patent/TW201311674A/zh unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009543836A (ja) * | 2006-07-14 | 2009-12-10 | グラクソ グループ リミテッド | インドール化合物 |
| WO2012069917A1 (en) * | 2010-11-26 | 2012-05-31 | Lupin Limited | Bicyclic gpr119 modulators |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019533022A (ja) * | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| JP2025041715A (ja) * | 2016-10-24 | 2025-03-26 | ヤンセン ファーマシューティカ エヌ．ベー． | 化合物及びその使用 |
| US12433880B2 (en) | 2017-01-06 | 2025-10-07 | Janssen Pharmaceutica Nv | Methods for the treatment of neurological disorders |
| US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US12275723B2 (en) | 2017-10-24 | 2025-04-15 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US12180221B2 (en) | 2018-03-23 | 2024-12-31 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US12268687B2 (en) | 2019-11-13 | 2025-04-08 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012267797A1 (en) | 2014-01-09 |
| KR20140041519A (ko) | 2014-04-04 |
| EP2718283A1 (en) | 2014-04-16 |
| TW201311674A (zh) | 2013-03-16 |
| RU2013157374A (ru) | 2015-07-20 |
| BR112013030939A2 (pt) | 2016-12-06 |
| WO2012169649A1 (en) | 2012-12-13 |
| AU2012267797A2 (en) | 2014-05-22 |
| MX2013014427A (es) | 2014-01-23 |
| CA2833507A1 (en) | 2012-12-13 |
| CN103748087A (zh) | 2014-04-23 |
| EP2718283A4 (en) | 2014-10-29 |
| US20140057895A1 (en) | 2014-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510708A (ja) | インダゾール誘導体およびピロロピリジン誘導体ならびにその医薬用途 | |
| JP2013010719A (ja) | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 | |
| AU2013276617B2 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| JP2014133739A (ja) | インダゾール誘導体またはピロロピリジン誘導体からなる医薬 | |
| DK2545045T3 (en) | PIPERIDINE-4-YL-azetidine derivatives AS JAK1 INHIBITORS | |
| CA3222144A1 (en) | Substituted indole compounds and methods of use thereof | |
| WO2014092104A1 (ja) | オキサジアゾール誘導体とその医薬用途 | |
| CN112585135B (zh) | 作为毒蕈碱m1和/或m4受体的激动剂的噁二唑 | |
| JP5315244B2 (ja) | アザビシクロヘキサン誘導体の使用 | |
| AU2014356583B2 (en) | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl | |
| CN107406449A (zh) | 作为毒蕈碱m1受体和/或m4受体的激动剂的螺环化合物 | |
| JP2013515033A (ja) | オレキシン受容体アンタゴニストとしてのジアザ−スピロ［５．５］ウンデカン類 | |
| JP5237807B2 (ja) | ドーパミンｄ３受容体の調節因子としてのトリアゾール誘導体 | |
| KR20170048563A (ko) | 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도 | |
| CN102639526B (zh) | 作为5-ht4受体配体的1,2-二氢-2-氧代喹啉化合物 | |
| CA3234429A1 (en) | Ras inhibitors, compositions and methods of use thereof | |
| TW202309006A (zh) | 作為ｓｉｇｍａ配體的新穎吡啶磺醯胺衍生物、其製備方法及用途，以及包含該吡啶－磺醯胺衍生物的醫藥組成物 | |
| JP2013237634A (ja) | 縮環イミダゾロン誘導体 | |
| TW202309017A (zh) | 作為Ｓｉｇｍａ配體的１Ｈ－吡唑衍生物 | |
| WO1999028307A1 (en) | Alicyclic acylated heterocyclic derivatives | |
| TW202304448A (zh) | 作為西格瑪配位基的新（高）哌啶基雜環 | |
| AU2019257385A1 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
| HK1173140B (en) | 1,2-dihydro-2-oxoquinoline compounds a 5-ht4 receptor ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131010 |
|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20131009 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131010 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140423 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150113 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150512 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140107 |